99 related articles for article (PubMed ID: 15918519)
1. The potential anti-hBV effect of amantadine in combination with ursodeoxycholic acid and biphenyl dimethyl dicarboxylate in hepG2 2.2.15 cells.
Joo SS; Lee DI
Arch Pharm Res; 2005 Apr; 28(4):451-7. PubMed ID: 15918519
[TBL] [Abstract][Full Text] [Related]
2. Interferon signal transduction of biphenyl dimethyl dicarboxylate/amantadine and anti-HBV activity in HepG2 2.2.15.
Joo SS; Won TJ; Kim MJ; Hwang KW; Lee DI
Arch Pharm Res; 2006 May; 29(5):405-11. PubMed ID: 16756086
[TBL] [Abstract][Full Text] [Related]
3. [Effects of amantadine and biphenyl dimethyl dicarboxylate on hepatitis B virus in hepatitis B virus replication mice].
Liu F; Jiang Z; Zhou Q; Yu Y; Meng H; Shi Y
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2014 Apr; 31(2):400-4. PubMed ID: 25039150
[TBL] [Abstract][Full Text] [Related]
4. Role of ISGF3 in modulating the anti-hepatitis B virus activity of interferon-alpha in vitro.
Zhang Q; Wang Y; Wei L; Jiang D; Wang JH; Rao HY; Zhu L; Chen H; Fei R; Cong X
J Gastroenterol Hepatol; 2008 Nov; 23(11):1747-61. PubMed ID: 17559358
[TBL] [Abstract][Full Text] [Related]
5. Anti-hepatitis B virus activity of α-DDB-FNCG, a novel nucleoside-biphenyldicarboxylate compound in vitro and in vivo.
Yang Q; Zhao X; Yu W; He W; Fang X; Zang L; Wan N; Wang Q; Zheng L; Chang J
J Pharmacol Sci; 2014; 126(3):208-15. PubMed ID: 25409748
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of hepatitis B virus by D-fraction from Grifola frondosa: synergistic effect of combination with interferon-alpha in HepG2 2.2.15.
Gu CQ; Li J; Chao FH
Antiviral Res; 2006 Nov; 72(2):162-5. PubMed ID: 16846649
[TBL] [Abstract][Full Text] [Related]
7. Protocatechuic acid inhibits hepatitis B virus replication by activating ERK1/2 pathway and down-regulating HNF4α and HNF1α in vitro.
Dai XQ; Cai WT; Wu X; Chen Y; Han FM
Life Sci; 2017 Jul; 180():68-74. PubMed ID: 28504115
[TBL] [Abstract][Full Text] [Related]
8. Antiviral potential of interferon-omega on hepatitis B virus replication in human hepatoma cells.
Hagelstein J; Kist A; Stremmel W; Galle PR
Arzneimittelforschung; 1998 Mar; 48(3):343-7. PubMed ID: 9553691
[TBL] [Abstract][Full Text] [Related]
9. Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus.
Tsuge M; Uchida T; Hiraga N; Kan H; Makokha GN; Abe-Chayama H; Miki D; Imamura M; Ochi H; Hayes CN; Shimozono R; Iwamura T; Narumi H; Suzuki T; Kainoh M; Taniguchi T; Chayama K
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373196
[TBL] [Abstract][Full Text] [Related]
10. Suppression of hepatitis B virus replication by microRNA-199a-3p and microRNA-210.
Zhang GL; Li YX; Zheng SQ; Liu M; Li X; Tang H
Antiviral Res; 2010 Nov; 88(2):169-75. PubMed ID: 20728471
[TBL] [Abstract][Full Text] [Related]
11. Antisense oligonucleotides targeted against asialoglycoprotein receptor 1 block human hepatitis B virus replication.
Yang J; Bo XC; Ding XR; Dai JM; Zhang ML; Wang XH; Wang SQ
J Viral Hepat; 2006 Mar; 13(3):158-65. PubMed ID: 16475991
[TBL] [Abstract][Full Text] [Related]
12. Anti-hepatitis B virus activities of α-DDB-FNC, a novel nucleoside-biphenyldicarboxylate compound in cells and ducks, and its anti-immunological liver injury effect in mice.
Yang Q; Zhao X; Zang L; Fang X; Zhao J; Yang X; Wang Q; Zheng L; Chang J
Antiviral Res; 2012 Dec; 96(3):333-9. PubMed ID: 23098744
[TBL] [Abstract][Full Text] [Related]
13. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B virus sensitivity to interferon-α in hepatocytes is more associated with cellular interferon response than with viral genotype.
Shen F; Li Y; Wang Y; Sozzi V; Revill PA; Liu J; Gao L; Yang G; Lu M; Sutter K; Dittmer U; Chen J; Yuan Z
Hepatology; 2018 Apr; 67(4):1237-1252. PubMed ID: 29059468
[TBL] [Abstract][Full Text] [Related]
15. PTD-fused p53 as a potential antiviral agent directly suppresses HBV transcription and expression.
Chu X; Wu B; Fan H; Hou J; Hao J; Hu J; Wang B; Liu G; Li C; Meng S
Antiviral Res; 2016 Mar; 127():41-9. PubMed ID: 26784393
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of hepatitis B virus DNA replicative intermediate forms by recombinant interferon-gamma.
Parvez MK; Sehgal D; Sarin SK; Basir SF; Jameel S
World J Gastroenterol; 2006 May; 12(19):3006-14. PubMed ID: 16718779
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication in vitro.
Vincent IE; Lucifora J; Durantel D; Hantz O; Chemin I; Zoulim F; Trepo C
Antivir Ther; 2009; 14(1):131-5. PubMed ID: 19320247
[TBL] [Abstract][Full Text] [Related]
18. Anti-hepatitis B virus activity of α-DDB-DU, a novel nucleoside analogue, in vitro and in vivo.
Zheng LY; Zang LM; Yang QH; Yu WQ; Fang XZ; Zhang YH; Zhao XJ; Wan N; Zhang YT; Wang QD; Chang JB
Eur J Pharmacol; 2013 Feb; 702(1-3):258-63. PubMed ID: 23415746
[TBL] [Abstract][Full Text] [Related]
19. KNK437 Inhibits Replication and Transcription of the Hepatitis B Virus.
Hu K; Huang Y; Mu J; Cheng Z; Zhu X
Bing Du Xue Bao; 2017 Jan; 33(1):24-35. PubMed ID: 30702818
[TBL] [Abstract][Full Text] [Related]
20. Whole genome expression profiling of hepatitis B virus-transfected cell line reveals the potential targets of anti-HBV drugs.
Ding XR; Yang J; Sun DC; Lou SK; Wang SQ
Pharmacogenomics J; 2008 Feb; 8(1):61-70. PubMed ID: 17505500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
